Preclinical studies and Phase I

In this channel, you can find the latest news and updates on lead candidates in preclinical and Phase I clinical trials.

Porcine model may be valuable in testing novel drug candidates to minimize failure rate

Member Exclusive

News, Novel lead compounds, Preclinical studies and Phase I, Technologies and methodologies

Porcine model may be valuable in testing novel drug candidates to minimize failure rate

Jul 28, 2017

What structural modifications can be used for BRD4 inhibitors for their use in leukemia therapy?

Member Exclusive

Spotlight on preclinical testing , From the journal, Novel lead compounds, Preclinical studies and Phase I

What structural modifications can be used for BRD4 inhibitors for their use in leukemia therapy?

Jul 18, 2017

MCN at Charles River Translational Target Validation Symposium - Timothy Harrison

Member Exclusive

Spotlight on drug target validation, Events, Novel lead compounds, Preclinical studies and Phase I

MCN at Charles River Translational Target Validation Symposium - Timothy Harrison

Jul 14, 2017

3-(Benzyloxy)-1-(5-[18F]fluoropentyl)-5-nitro-1H-indazole: A PET radiotracer to measure acetylcholinesterase in brain

Member Exclusive

From the journal, Preclinical studies and Phase I, Technologies and methodologies

3-(Benzyloxy)-1-(5-[18F]fluoropentyl)-5-nitro-1H-indazole: A PET radiotracer to measure acetylcholinesterase in brain

Jul 10, 2017

MCN at Charles River Translational Target Validation Symposium - Prem Premsrirut

Member Exclusive

Spotlight on drug target validation, Events, Preclinical studies and Phase I, Technologies and methodologies

MCN at Charles River Translational Target Validation Symposium - Prem Premsrirut

Jul 07, 2017

Simplified form of teixobactin inhibits multi-drug resistant bacteria

Member Exclusive

News, Novel lead compounds, Preclinical studies and Phase I

Simplified form of teixobactin inhibits multi-drug resistant bacteria

Jul 06, 2017

Combination immunotherapies may be beneficial in rhabdomyosarcoma therapy

News, Biopharmaceuticals and large molecules, Novel lead compounds, Preclinical studies and Phase I

Combination immunotherapies may be beneficial in rhabdomyosarcoma therapy

Jul 03, 2017

New drug may provide colorectal cancer patients with a more effective and less toxic treatment

Member Exclusive

News, Novel lead compounds, Preclinical studies and Phase I

New drug may provide colorectal cancer patients with a more effective and less toxic treatment

Jun 27, 2017

New technology aims to chip away at drug testing times

Member Exclusive

Spotlight on preclinical testing , News, Preclinical studies and Phase I, Technologies and methodologies

New technology aims to chip away at drug testing times

May 19, 2017

First photoactive drug shows promise for pain treatment

Member Exclusive

Spotlight on preclinical testing , News, Drug delivery, Therapeutic challenges, Preclinical studies and Phase I

First photoactive drug shows promise for pain treatment

May 03, 2017

Antibiotic combination therapy overcomes Carbapenem-resistant Enterobacteriaceae

Member Exclusive

News, Drug discovery approaches, Preclinical studies and Phase I

Antibiotic combination therapy overcomes Carbapenem-resistant Enterobacteriaceae

Mar 20, 2017

Novel class of proteasome inhibitor may provide benefit in cancer treatment

Member Exclusive

News, Novel lead compounds, Preclinical studies and Phase I

Novel class of proteasome inhibitor may provide benefit in cancer treatment

Mar 10, 2017

Diabetes management strategies: can nanoparticles be used to therapeutically deliver insulin?

Member Exclusive

From the journal, Drug delivery, Preclinical studies and Phase I

Diabetes management strategies: can nanoparticles be used to therapeutically deliver insulin?

Feb 24, 2017

Research turns the spotlight onto Mangiferin properties

Spotlight on preclinical testing , From the journal, Drug discovery approaches, Preclinical studies and Phase I

Research turns the spotlight onto Mangiferin properties

Future Science OA

Jan 17, 2017

Indole-fused benzooxazepines: a new structural class of anticancer agents?

Spotlight on preclinical testing , From the journal, Novel lead compounds, Preclinical studies and Phase I, Therapeutic targets

Indole-fused benzooxazepines: a new structural class of anticancer agents?

Future Science OA

Jan 05, 2017

Notch signaling inhibitor shows promise for cancer treatment in Phase I trial

Member Exclusive

News, Novel lead compounds, Preclinical studies and Phase I

Notch signaling inhibitor shows promise for cancer treatment in Phase I trial

Dec 06, 2016

Experimental drug shows promise for prostate cancer

Member Exclusive

News, Preclinical studies and Phase I, Therapeutic targets, Cancer

Experimental drug shows promise for prostate cancer

Nov 23, 2016

Cancer drug development halted following trial deaths

Member Exclusive

Drug regulation and industry, Therapeutic challenges, Preclinical studies and Phase I, Cancer

Cancer drug development halted following trial deaths

Nov 16, 2016

Member Exclusive

News, Novel lead compounds, Preclinical studies and Phase I

Alzheimer’s disease: experimental therapeutic shows promise

Research presented at the Anesthesiology® 2016 annual meeting shows an experimental drug with promise in treating Alzheimer’s disease in mice.

Nov 02, 2016

Member Exclusive

News, Novel lead compounds, Preclinical studies and Phase I

Novel compound shows promise in treating multiple human cancers

A new compound has been shown by researchers at the Walter and Eliza Hall Institute (Melbourne, Australia) and Servier (Neuilly-sur-Seine, France) to block a protein essential to the sustained growth of up to a quarter of all cancers.

Oct 27, 2016